Loading organizations...
§ Private Profile · Melbourne, Victoria, Australia
Clinical-stage biotech developing immunotherapies for food allergies. Lead product PVX108 is in Phase 2 trials for peanut allergy.
Aravax is a clinical-stage biotechnology company based in Melbourne, Victoria, Australia, that develops next-generation peptide-based immunotherapies for food allergies. The organization's lead clinical candidate, PVX108, is currently undergoing fully recruited Phase 2 clinical trials across the United States and Australia, and is designed to reprogram the immune system's response to peanuts without exposing patients to whole peanut proteins. To support its ongoing clinical programs and broader international expansion, the company secured $42 million in Series B financing in late 2022 and recently announced a $10 million investment to establish manufacturing operations in the United Kingdom. This clinical development pipeline is financially backed by a syndicate of prominent institutional investors, including Brandon Capital, Tenmile, and the Novartis Venture Fund. Aravax was founded in 2015 by Sara Prickett and Professor Robyn O'Hehir as a spin-out from Monash University and Alfred Health.
Aravax has raised $42.0M across 1 funding round.
Aravax has raised $42.0M in total across 1 funding round.
Aravax has raised $42.0M in total across 1 funding round.
Aravax's investors include Agati Capital, Brandon Capital, Grant Dooley, Novartis, Tenmile, Uniseed.
Aravax has raised $42.0M across 1 funding round. Most recently, it raised $42.0M Series B in January 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 23, 2024 | $42M Series B | — | Agati Capital, Brandon Capital, Grant Dooley, Novartis, Tenmile, Uniseed | Announced |